Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,468 | 0,522 | 18:05 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.09. | Oncopeptides AB: Oncopeptides' rights issue oversubscribed to approximately 157 percent | 150 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
ONCOPEPTIDES Aktie jetzt für 0€ handeln | |||||
28.08. | Oncopeptides AB: Oncopeptides publishes disclosure document regarding rights issue | 258 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
27.08. | Oncopeptides - Targeted oncology with commercial momentum | 339 | Edison Investment Research | Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved... ► Artikel lesen | |
26.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.08.2025 | 228 | Xetra Newsboard | Das Instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY wird ex Kapitalmassnahme gehandelt am 26.08.2025 The instrument 14B0 NO0013470534 HUDDLY AS NK -,0625 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
25.08. | Oncopeptides AB: Oncopeptides enters into additional guarantee commitments, rights issue fully guaranteed | 133 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
21.08. | Oncopeptides Q2 2025 slides: 135% sales growth overshadowed by rights issue announcement | 3 | Investing.com | ||
21.08. | Oncopeptides AB: Oncopeptides publishes Q2 report 2025 | 147 | GlobeNewswire (Europe) | Stockholm - August 21, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2025.
"This... ► Artikel lesen | |
30.07. | Oncopeptides AB: Oncopeptides Partners with SD Pharma to further broaden Pepaxti reach in Spain | 256 | GlobeNewswire (Europe) | Stockholm, July 30, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces a partnership with SD Pharma, a leading Spanish pharmaceutical... ► Artikel lesen | |
09.07. | Oncopeptides AB: Oncopeptides announces net sales for Q2 2025 | 266 | GlobeNewswire (Europe) | Stockholm, July 9, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the second quarter of 2025.
Oncopeptides... ► Artikel lesen | |
22.05. | Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides AB (publ) | 218 | GlobeNewswire (Europe) | Stockholm, Sweden - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 22 May 2025. At the Annual General Meeting, the following principal resolutions were passed.
The... ► Artikel lesen | |
20.05. | Oncopeptides AB: Oncopeptides launches new real-world evidence study of Pepaxti in Spain, first patient enrolled | 319 | GlobeNewswire (Europe) | Stockholm, May 20, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the first patient has been enrolled in its new... ► Artikel lesen | |
15.05. | Oncopeptides Q1 2025 slides: 160% sales growth as European expansion accelerates | 4 | Investing.com | ||
15.05. | Oncopeptides AB: Oncopeptides publishes Q1 report 2025 | 252 | GlobeNewswire (Europe) | Stockholm - May 15, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2025.
"The first... ► Artikel lesen | |
16.04. | Oncopeptides AB: New Real-World Data support effectiveness and tolerability of Pepaxti in heavily pretreated Multiple Myeloma patients | 261 | GlobeNewswire (Europe) | Stockholm, April 16, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further... ► Artikel lesen | |
27.02. | Oncopeptides AB: Oncopeptides publishes year-end report 2024 | 436 | GlobeNewswire (Europe) | Stockholm - February 27, 2025 - Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2024.
"Pepaxti sales increased about 35 percent... ► Artikel lesen | |
07.11.24 | Oncopeptides AB: Oncopeptides publishes Q3 report 2024 | 301 | GlobeNewswire (Europe) | Stockholm - November 7, 2024 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2024.
"In the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 91,60 | +0,16 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
EVOTEC | 6,756 | -1,17 % | NetraMark Holdings, Evotec, Sartorius - Milliardengeschäfte im Blick! | Künstliche Intelligenz und Maschinelles Lernen sind mittlerweile in fast allen Branchen wichtige Schrittmacher. Wenn Pharmaunternehmen ein Medikament bis zur Marktreife entwickelt haben, sprudeln die... ► Artikel lesen | |
MEDIGENE | 0,060 | -9,34 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
QIAGEN | 41,110 | +0,85 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
CUREVAC | 4,654 | -0,21 % | CureVac-Alarm: Insidern zufolge steht eine spektakuläre Trendwende bevor - handeln, bevor es zu spät ist!!! | ||
MODERNA | 23,940 | -4,49 % | MODERNA INC - Jetzt beginnt das Biotech-Comeback! | ||
PAION | 0,011 | 0,00 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
VALNEVA | 4,844 | +2,54 % | Valneva korrigiert Finanzziele - Hoffnung bleibt auf Lyme-Impfstoff ab 2027 | Valneva hat eine neue Kreditfazilität über bis zu 500 Millionen US-Dollar mit von Pharmakon Advisors verwalteten Fonds abgeschlossen. Eine erste Tranche von 215 Millionen US-Dollar dient zur vollständigen... ► Artikel lesen | |
AMGEN | 255,95 | +1,01 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
NOVAVAX | 7,535 | -1,61 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
STRYKER | 321,60 | -0,37 % | Stryker to roll out training center model in Ireland with first in Limerick | ||
BIOGEN | 129,25 | -0,42 % | Erste Patienten bekommen Alzheimer-Mittel Lecanemab der Hersteller Biogen und Eisai | BERLIN (dpa-AFX) - Seit gut einem Monat ist das Alzheimer-Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten mit der Therapie... ► Artikel lesen | |
BIOFRONTERA | 2,810 | +1,81 % | Benchmark reiterates Buy rating on Biofrontera stock amid tariff concerns | ||
HEIDELBERG PHARMA | 3,070 | -1,60 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma gibt Aktualisierung der Prognose bekannt | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Prognoseänderung
Heidelberg Pharma AG gibt Aktualisierung der Prognose bekannt
06.10.2025 / 15:58 CET/CEST
Veröffentlichung einer... ► Artikel lesen | |
ILLUMINA | 84,54 | +0,54 % | ILMN Stock Set to Benefit From the Launch of New BioInsight Division |